74 related articles for article (PubMed ID: 9229329)
1. Phase I dose-finding and pharmacokinetic trial of irinotecan hydrochloride (CPT-11) using a once-every-three-week dosing schedule for patients with advanced solid tumor malignancy.
Pitot HC; Goldberg RM; Reid JM; Sloan JA; Skaff PA; Erlichman C; Rubin J; Burch PA; Adjei AA; Alberts SA; Schaaf LJ; Elfring G; Miller LL
Clin Cancer Res; 2000 Jun; 6(6):2236-44. PubMed ID: 10873073
[TBL] [Abstract][Full Text] [Related]
2. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
Armand JP; Extra YM; Catimel G; Abigerges D; Marty M; Clavel M
Ann Oncol; 1996 Oct; 7(8):837-42. PubMed ID: 8922198
[TBL] [Abstract][Full Text] [Related]
3. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
Abigerges D; Chabot GG; Armand JP; Hérait P; Gouyette A; Gandia D
J Clin Oncol; 1995 Jan; 13(1):210-21. PubMed ID: 7799022
[TBL] [Abstract][Full Text] [Related]
4. CPT-11: the European clinical development.
Terret C; Couteau C; Armand JP
J Infus Chemother; 1996; 6(3):152-7. PubMed ID: 9229329
[TBL] [Abstract][Full Text] [Related]
5. CPT-11. The European experience.
Armand JP; Terret C; Couteau C; Rixe O
Ann N Y Acad Sci; 1996 Dec; 803():282-91. PubMed ID: 8993522
[TBL] [Abstract][Full Text] [Related]
6. CPT-11: clinical experience in phase I studies.
Armand JP
Semin Oncol; 1996 Feb; 23(1 Suppl 3):27-33. PubMed ID: 8633250
[TBL] [Abstract][Full Text] [Related]
7. [Irinotecan: various administration schedules, study of drug combinations, phase I experience].
Boige V; Raymond E; Armand JP
Bull Cancer; 1998 Dec; Spec No():26-32. PubMed ID: 9932081
[TBL] [Abstract][Full Text] [Related]
8. [CPT-11 (irinotecan)--evidence from molecular and pharmacological studies and clinical applications].
Isobe T; Ishikawa N; Oguri T
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1267-78. PubMed ID: 10945026
[TBL] [Abstract][Full Text] [Related]
9. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile.
Rougier P; Bugat R
Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252
[TBL] [Abstract][Full Text] [Related]
10. [Irinotecan hydrochloride (CPT-11)].
Furue H
Gan To Kagaku Ryoho; 1994 Apr; 21(5):709-17. PubMed ID: 8154899
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]